サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1737516

外来輸液センターの世界市場

Ambulatory Infusion Centers

出版日
ページ情報
英文 190 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
外来輸液センターの世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

外来輸液センターの世界市場は2030年までに964億米ドルに達する見込み

2024年に509億米ドルと推定される外来輸液センターの世界市場は、2024～2030年の分析期間においてCAGR 11.3%で成長し、2030年には964億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血液製剤注入は、CAGR 12.2%を記録し、分析期間終了時には332億米ドルに達すると予測されます。鉄剤療法セグメントの成長率は、分析期間中CAGR 12.0％と推定されます。

米国市場は134億米ドル、中国はCAGR10.3%で成長すると予測

米国の外来輸液センター市場は2024年に134億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに148億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.1%と9.1%と予測されています。欧州では、ドイツがCAGR約8.8%で成長すると予測されています。

世界の外来輸液センター市場- 主要動向と促進要因のまとめ

外来輸液センターが病院ベースの輸液ケアに代わる患者中心の選択肢として支持を集める理由とは？

外来輸液センター（AIC）は、ヘルスケアシステムがコスト削減、患者の利便性向上、病院の負担軽減のために、入院モデルから外来モデルへの移行が進む中、世界的に急速な普及が進んでいます。AICは、自己免疫疾患、がん、多発性硬化症、原発性免疫不全症などの慢性疾患で、生物製剤や特殊な薬剤、長期の点滴治療を必要とする患者に対して、急性期ではない環境で点滴治療を提供します。病院外来（HOPD）とは異なり、AICは一般的に独立型またはクリニックベースの施設であり、待ち時間が短く、より個別化された治療環境で、質の高い輸液治療を大幅に低コストで提供します。特に米国では、民間保険会社やメディケアアドバンテージプランが、高コストの病院輸液から患者を遠ざける傾向を強めています。

定期的な輸液療法を必要とする慢性疾患や複雑な疾患の増加により、スケーラブルで分散型の治療ソリューションの必要性が高まっています。患者がAICを好む理由は、アクセスのしやすさ、合理的なスケジューリング、院内感染への曝露の少なさです。さらに、特に腫瘍学、リウマチ学、神経学などの専門的な薬剤開発の進歩により、臨床的に管理されながらコストを最適化した環境で投与されなければならない輸液療法のパイプラインが着実に構築されつつあります。AICは安全性、有効性、効率性の理想的な交差点として台頭してきており、柔軟なスケジューリング、より自宅に近いケア、連携した症例管理などを提供します。

診療報酬動向と臨床イノベーションは、AICのビジネスモデルをどのように再構築しているのでしょうか？

進化する償還構造とバリューベースケアの義務化は、外来輸液センターの拡大に大きく影響しています。幾つかの市場では、HOPDの診療報酬が高額であるとしてますます精査されるようになり、支払者の方針が医療現場の最適化を優先するように再調整されつつあります。その結果、一般的に輸液1回あたりのコストが40％から60％低いAICが保険会社の間で選好されるようになっており、保険会社は給付設計、患者教育、ネットワーク契約を通じて医療施設のシフトを促しています。バイオシミラーの利用可能性も輸液の経済性を再構築しており、AICはインフリキシマブ、リツキシマブ、トラスツズマブのような大量の治療薬で高いマージンを維持しながら、競争力のある価格を提供することができます。このようなシフトは、独立した外来輸液センターモデルの実行可能性を強化し、外来輸液ネットワークの拡大を目指す医師グループ、医療システム、プライベート・エクイティ投資家の関心を喚起しています。

技術統合もまた、AICの運営を変容させつつあります。輸液ワークフローに合わせた電子カルテ（EHR）、安全警告機能付きスマート輸液ポンプ、リアルタイムスケジューリングシステムは、ケアコーディネーションと臨床の安全性を向上させています。臨床プロトコールは、薬剤の調製、投与、モニタリングの一貫性を確保するために標準化されつつあり、看護師養成プログラムは、輸液認定者の需要を満たすために拡大されています。AICの中には、ケアの継続性を高めるために、遠隔医療相談、遠隔患者モニタリング、専門医との統合ケアパスを取り入れているところもあります。さらに、データ分析と集団健康管理ツールは、患者の転帰を追跡し、治療レジメンを最適化するために使用されており、アウトカムベースの償還への移行をサポートしています。こうしたイノベーションにより、AICの役割は、基本的な手続きセンターから、統合された慢性疾患管理ハブへと高まりつつあります。

需要はどこで加速し、どの治療領域が販売量を牽引しているか？

外来輸液センターの需要は、北米、西欧、アジア太平洋の一部地域の都市部と郊外の両方で加速しており、外来インフラは慢性疾患の流行に合わせて進化しています。米国は最も成熟した市場であり、現在では数千のAICが複数の専門診療所、独立したネットワーク、統合医療システムの一部として運営されています。特に関節リウマチ、クローン病、潰瘍性大腸炎、乾癬などで使用される大量の生物学的製剤については、保険会社の支援による輸液給付管理によって、病院からAICへの患者の移行が加速しています。欧州では、ヘルスケア支出削減への圧力が高まっており、各国政府は、特に腫瘍学や血液学の治療において、外来点滴の提供モデルを模索しています。ドイツ、英国、オランダなどの国では、地域ベースの輸液ネットワークや在宅輸液の試験的導入に投資しています。

外来輸液センターの売上を牽引している治療分野は、免疫学、神経学、腫瘍学、感染症などです。モノクローナル抗体療法、免疫グロブリン静注（IVIG）、鉄剤注入は、最も件数の多いサービスの一つです。がん分野では、維持化学療法、免疫療法、制吐剤や水分補給療法などの支持療法へのAIC導入が増加しています。神経内科では、多発性硬化症や重症筋無力症などの疾患で、それぞれナタリズマブやエクリズマブの定期的な輸注が必要とされているが、アクセスを改善し、移動の負担を最小限にするため、AICで行われることが多いです。COVID-19パンデミックは、緊急治療におけるAICの役割をさらに浮き彫りにしており、モノクローナル抗体治療や抗ウイルス剤の点滴療法は、病院の負担を軽減するために外来で行われています。希少疾患や専門的な適応症で新たな輸液療法が発売されるにつれ、AICは費用対効果が高く、高頻度の外来輸液を行うための既定のチャネルになる準備が整っています。

世界の外来輸液センター市場の成長の原動力は？

外来輸液センター市場の成長は、特殊な生物製剤に対する需要の高まり、輸液ケアをより低コストの環境へ移行させようとする支払者の圧力、利便性と個別ケアに対する患者の期待の進化など、いくつかの要因によってもたらされます。主な成長要因の1つは、院外での継続的な投与を必要とする複雑な輸液治療薬のパイプラインが拡大していることです。医薬品メーカーが新しいモノクローナル抗体、遺伝子治療薬、長時間作用型注射薬を市場に投入するにつれ、安全で拡張性の高い輸液インフラに対するニーズは高まり続けています。AICは、管理された看護師の監視下でこれらの療法を提供するプラットフォームを提供する一方、高い患者スループットと最小限のインフラオーバーヘッドをサポートします。

コストの透明性とともに、償還の最適化もAICの採用をさらに後押ししています。保険会社は医療現場ステアリングプログラムを通じて患者を積極的に外来に誘導しており、輸液療法のコストを1回あたり数千ドル削減するのに役立っています。さらに、ベンチャーキャピタルや医療システムへの投資が増加し、AICネットワークの地理的拡大、標準化、運営統合に拍車をかけています。人口動態の動向、特に高齢化と慢性的な自己免疫疾患、神経疾患、腫瘍性疾患の蔓延は、長期的な需要基盤の拡大をもたらしています。ケアコーディネーション、デジタルヘルス統合、患者エンゲージメントにおける革新は、AICが包括的で縦断的な輸液サポートを提供することを可能にしています。こうした臨床的、財政的、人口動態的な力学が交錯することで、市場の拡大が加速しています。外来輸液センターは、分散型ヘルスケアの未来において、複雑な生物製剤や慢性輸液療法を管理するための世界スタンダードとなるのだろうか？

セグメント

治療タイプ（血液製品輸液、鉄療法、ステロイド輸液、免疫グロブリン療法、治療的瀉血、プラズマフェレーシス、凝固因子補充療法、その他の治療タイプ）、アプリケーション（糖尿病、がん、骨疾患、神経変性疾患、その他のアプリケーション）、エンドユーザー（病院、専門クリニック、在宅医療現場、その他のエンドユーザー）

調査対象企業の例（注目の42社）

  • Amedisys, Inc.
  • AmerisourceBergen Corporation
  • Arnot Health
  • Baxter International Inc.
  • Cedars-Sinai
  • CHI Health at Home
  • ChristianaCare
  • CitusHealth
  • Cleveland Clinic
  • Coram CVS Specialty Infusion Services
  • CVS Health
  • FlexCare Infusion Centers
  • Fresenius Kabi
  • Hawaii Medical Service Association
  • Healix, LLC
  • InfuCare Rx
  • InfuSystem Holdings, Inc.
  • IVX Health
  • KabaFusion
  • McKesson Corporation

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33442

Global Ambulatory Infusion Centers Market to Reach US$96.4 Billion by 2030

The global market for Ambulatory Infusion Centers estimated at US$50.9 Billion in the year 2024, is expected to reach US$96.4 Billion by 2030, growing at a CAGR of 11.3% over the analysis period 2024-2030. Blood Product Infusion, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$33.2 Billion by the end of the analysis period. Growth in the Iron Therapy segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.4 Billion While China is Forecast to Grow at 10.3% CAGR

The Ambulatory Infusion Centers market in the U.S. is estimated at US$13.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.8 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.1% and 9.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR.

Global Ambulatory Infusion Centers Market - Key Trends & Drivers Summarized

Why Are Ambulatory Infusion Centers Gaining Traction as a Patient-Centric Alternative to Hospital-Based Infusion Care?

Ambulatory infusion centers (AICs) are experiencing rapid global adoption as healthcare systems increasingly shift from inpatient to outpatient models to reduce costs, improve patient convenience, and alleviate hospital burdens. AICs offer infusion therapy in a non-acute setting for patients requiring biologics, specialty medications, or long-term intravenous treatments for chronic conditions such as autoimmune diseases, cancer, multiple sclerosis, and primary immunodeficiencies. Unlike hospital outpatient departments (HOPDs), AICs are typically standalone or clinic-based facilities that offer high-quality infusion care at a significantly lower cost, with shorter wait times and a more personalized treatment environment. This care model aligns with payer priorities, particularly in the U.S., where commercial insurers and Medicare Advantage plans are increasingly steering patients away from high-cost hospital infusions.

The rising prevalence of chronic and complex diseases requiring regular infusion therapy is amplifying the need for scalable, decentralized treatment solutions. Patients prefer AICs for their accessibility, streamlined scheduling, and lower exposure to nosocomial infections-a key consideration for immunocompromised populations. Furthermore, advancements in specialty drug development, particularly in oncology, rheumatology, and neurology, are creating a steady pipeline of infused therapies that must be administered in clinically controlled but cost-optimized settings. AICs are emerging as the ideal intersection of safety, efficacy, and efficiency, offering flexible scheduling, closer-to-home care, and coordinated case management-all critical factors in improving treatment adherence and long-term outcomes.

How Are Reimbursement Trends and Clinical Innovations Reshaping the AIC Business Model?

Evolving reimbursement structures and value-based care mandates are significantly influencing the expansion of ambulatory infusion centers. In several markets, payer policies are being recalibrated to favor site-of-care optimization, with reimbursement rates for HOPDs increasingly scrutinized for high overhead costs. As a result, AICs-which typically operate at 40% to 60% lower cost per infusion-are gaining preference among insurers, who are encouraging site shifts through benefit design, patient education, and network contracts. The availability of biosimilars is also reshaping infusion economics, enabling AICs to offer competitive pricing while maintaining strong margins on high-volume therapeutics such as infliximab, rituximab, and trastuzumab. These shifts are reinforcing the viability of independent infusion center models and sparking interest from physician groups, health systems, and private equity investors seeking to scale outpatient infusion networks.

Technological integration is also transforming AIC operations. Electronic health records (EHRs) tailored for infusion workflows, smart infusion pumps with safety alerts, and real-time scheduling systems are improving care coordination and clinical safety. Clinical protocols are being standardized to ensure consistency in drug preparation, dosing, and monitoring, while nurse training programs are being expanded to meet demand for infusion-certified personnel. Some AICs are incorporating telehealth consults, remote patient monitoring, and integrated care pathways with specialists to enhance continuity of care. Moreover, data analytics and population health tools are being used to track patient outcomes and optimize therapy regimens, supporting the transition to outcomes-based reimbursement. These innovations are elevating the role of AICs from basic procedural centers to integrated chronic disease management hubs.

Where Is Demand Accelerating and Which Therapeutic Areas Are Driving Volume?

Demand for ambulatory infusion centers is accelerating in both urban and suburban regions across North America, Western Europe, and selected parts of Asia-Pacific where outpatient infrastructure is evolving in line with chronic disease prevalence. The U.S. is the most mature market, with thousands of AICs now operating as part of multi-specialty practices, independent networks, and integrated health systems. Insurer-backed infusion benefit management is accelerating patient migration from hospitals to AICs, especially for high-volume biologic therapies used in rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and psoriasis. In Europe, rising pressure to reduce healthcare expenditures is pushing governments to explore outpatient infusion delivery models, particularly for oncology and hematology care. Countries such as Germany, the U.K., and the Netherlands are investing in community-based infusion networks and home infusion pilots.

Therapeutic areas driving infusion center volume include immunology, neurology, oncology, and infectious diseases. Monoclonal antibody therapies, intravenous immunoglobulin (IVIG), and iron infusions are among the highest-volume services. The oncology sector is seeing increased AIC adoption for maintenance chemotherapy, immunotherapy, and supportive care infusions such as antiemetics and hydration therapy. In neurology, diseases such as multiple sclerosis and myasthenia gravis are requiring routine infusions of natalizumab and eculizumab, respectively, often delivered in AICs to improve access and minimize travel burden. The COVID-19 pandemic has further spotlighted the role of AICs in emergency therapeutics, with monoclonal antibody treatments and antiviral IV therapies administered in outpatient settings to relieve hospital load. As new infused therapies are launched across rare disease and specialty indications, AICs are poised to become the default channel for cost-effective, high-frequency outpatient infusion delivery.

What Is Fueling the Growth of the Ambulatory Infusion Centers Market Globally?

The growth in the ambulatory infusion centers market is driven by several factors, including rising demand for specialty biologics, payer pressure to shift infusion care to lower-cost settings, and evolving patient expectations for convenience and personalized care. One of the primary growth drivers is the expanding pipeline of complex, infused therapeutics requiring ongoing administration outside the hospital environment. As drug manufacturers bring to market new monoclonal antibodies, gene therapies, and long-acting injectables, the need for safe, scalable infusion infrastructure continues to climb. AICs offer a platform to deliver these therapies under controlled, nurse-supervised conditions while supporting high patient throughput and minimal infrastructure overhead.

Reimbursement optimization, alongside cost transparency, is further strengthening AIC adoption. Insurers are actively directing patients to ambulatory settings through site-of-care steering programs, helping reduce infusion therapy costs by thousands of dollars per session. Additionally, rising venture capital and health system investments are fueling geographic expansion, standardization, and operational integration of AIC networks. Demographic trends-particularly aging populations and the growing prevalence of chronic autoimmune, neurologic, and oncologic conditions-are expanding the long-term demand base. Innovations in care coordination, digital health integration, and patient engagement are enabling AICs to offer comprehensive, longitudinal infusion support. These intersecting clinical, financial, and demographic dynamics are accelerating market expansion-raising the question: Will ambulatory infusion centers become the global standard for administering complex biologics and chronic infusion therapies in a decentralized healthcare future?

SCOPE OF STUDY:

The report analyzes the Ambulatory Infusion Centers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy, Other Therapy Types); Application (Diabetic, Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications); End-User (Hospitals, Specialty Clinics, Homecare Settings, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Amedisys, Inc.
  • AmerisourceBergen Corporation
  • Arnot Health
  • Baxter International Inc.
  • Cedars-Sinai
  • CHI Health at Home
  • ChristianaCare
  • CitusHealth
  • Cleveland Clinic
  • Coram CVS Specialty Infusion Services
  • CVS Health
  • FlexCare Infusion Centers
  • Fresenius Kabi
  • Hawaii Medical Service Association
  • Healix, LLC
  • InfuCare Rx
  • InfuSystem Holdings, Inc.
  • IVX Health
  • KabaFusion
  • McKesson Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Ambulatory Infusion Centers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Cost-Efficient Care Settings Drives Utilization of Ambulatory Infusion Centers
    • Expanding Use of Biologics and Specialty Therapies Boosts Demand for Ambulatory Infusion Centers
    • Patient Preference for Convenience and Shorter Visits Encourages Adoption of Ambulatory Infusion Centers
    • Technological Improvements in Infusion Equipment Enhance Operational Efficiency at Ambulatory Infusion Centers
    • Rising Burden of Chronic Illnesses Increases Reliance on Ambulatory Infusion Centers for Ongoing Care
    • Integration of Electronic Health Records Strengthens Clinical Capabilities of Ambulatory Infusion Centers
    • Retail and Standalone Infusion Clinics Expand Market Reach of Ambulatory Infusion Centers
    • Favorable Reimbursement Policies Support Continued Expansion of Ambulatory Infusion Centers
    • Emergence of Hybrid Home-and-Center Models Increases Versatility of Ambulatory Infusion Centers
    • Infection Control Protocols Improve Patient Confidence in Ambulatory Infusion Centers
    • Strategic Growth by Physician Groups and Pharmacy Chains Enhances Availability of Ambulatory Infusion Centers
    • Chronic Disease Management Trends Position Ambulatory Infusion Centers as Critical Healthcare Infrastructure
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ambulatory Infusion Centers Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Ambulatory Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Blood Product Infusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Blood Product Infusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Iron Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Iron Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Steroid Infusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Steroid Infusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Immunoglobulin Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Therapeutic Phlebotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Therapeutic Phlebotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Plasmapheresis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Plasmapheresis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clotting Factor Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Clotting Factor Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Bone Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Bone Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Diabetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Diabetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • CHINA
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe 6-Year Perspective for Ambulatory Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 70: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: France 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 72: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: France 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 76: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Germany 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 78: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Germany 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 82: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Italy 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 84: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Italy 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 88: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: UK 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 90: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: UK 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Ambulatory Infusion Centers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 106: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Therapy Type - Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by Therapy Type - Percentage Breakdown of Value Sales for Blood Product Infusion, Iron Therapy, Steroid Infusion, Immunoglobulin Therapy, Therapeutic Phlebotomy, Plasmapheresis, Clotting Factor Replacement Therapy and Other Therapy Types for the Years 2025 & 2030
    • TABLE 108: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by Application - Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by Application - Percentage Breakdown of Value Sales for Cancer, Bone Diseases, Neurodegenerative Diseases, Other Applications and Diabetic for the Years 2025 & 2030
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Ambulatory Infusion Centers by End-user - Hospitals, Specialty Clinics, Homecare Settings and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of World 6-Year Perspective for Ambulatory Infusion Centers by End-user - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics, Homecare Settings and Other End-Users for the Years 2025 & 2030

IV. COMPETITION